High-Mobility Group Box-1 Mediates Toll-Like Receptor 4–Dependent Angiogenesis

Objective—Inflammation is closely linked to angiogenesis, and Toll-like receptors (TLRs) are the key mediators of inflammatory responses. However, the impact of TLRs on angiogenesis is incompletely understood. In this study, we determined the involvement of TLRs in angiogenesis. Methods and Results—In a mouse model of alkali-induced corneal neovascularization (CNV), we found that CNV was attenuated in TLR4−/− but not TLR2−/− mice. Further study revealed that the absence of TLR4 led to decreased production of proangiogenic factors in association with reduced accumulation of macrophages at the site of wounds, which was associated with reduced expression of high-mobility group box-1 (HMGB1) protein, an endogenous ligand for TLR4. Topical application of HMGB1 to the injured cornea promoted CNV with increased macrophage accumulation in wild-type mice but not in TLR4−/− mice. HMGB1 treatment in vitro also promoted the production of proangiogenic factors by mouse macrophages in a TLR4-dependent manner. Furthermore, antagonists of HMGB1 and TLR4 reduced CNV and macrophage recruitment in the injured cornea of wild-type mice. Conclusion—Our results suggest that the release of HMGB1 in the wounds initiates TLR4-dependent responses that contribute to neovascularization. Thus, targeting HMGB1-TLR4 signaling cascade may constitute a novel therapeutic approach to angiogenesis-related diseases.

[1]  S. Su,et al.  Production of recombinant human HMGB1 and anti-HMGB1 rabbit serum. , 2011, International immunopharmacology.

[2]  Jinyue Hu,et al.  The expression of functional toll‐like receptor 4 is associated with proliferation and maintenance of stem cell phenotype in endothelial progenitor cells (EPCs) , 2010, Journal of cellular biochemistry.

[3]  M. Moskowitz,et al.  High-Mobility Group Box 1 Promotes Metalloproteinase-9 Upregulation Through Toll-Like Receptor 4 After Cerebral Ischemia , 2010, Stroke.

[4]  V. Shah,et al.  Endothelial cell toll‐like receptor 4 regulates fibrosis‐associated angiogenesis in the liver , 2010, Hepatology.

[5]  M. Bianchi,et al.  TLR4‐mediated skin carcinogenesis is dependent on immune and radioresistant cells , 2010, The EMBO journal.

[6]  S. Akira,et al.  A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release , 2010, Proceedings of the National Academy of Sciences.

[7]  E. Aronica,et al.  Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures , 2010, Nature Medicine.

[8]  G. Ghirlanda,et al.  High-Mobility Group Box-1 Protein Promotes Angiogenesis After Peripheral Ischemia in Diabetic Mice Through a VEGF-Dependent Mechanism , 2010, Diabetes.

[9]  Huan Yang,et al.  Fas (CD95) induces rapid, TLR4/IRAK4-dependent release of pro-inflammatory HMGB1 from macrophages , 2010, Journal of Inflammation.

[10]  J. Wang,et al.  Extracellular High Mobility Group Box-1 (HMGB1) Inhibits Enterocyte Migration via Activation of Toll-like Receptor-4 and Increased Cell-Matrix Adhesiveness* , 2009, The Journal of Biological Chemistry.

[11]  R. Dana,et al.  Growth Factors , Cytokines , Cell Cycle Molecules Contribution of Macrophages to Angiogenesis Induced by Vascular Endothelial Growth Factor Receptor-3-Specific Ligands , 2010 .

[12]  N. Mukaida,et al.  Enhanced experimental corneal neovascularization along with aberrant angiogenic factor expression in the absence of IL-1 receptor antagonist. , 2009, Investigative ophthalmology & visual science.

[13]  A. Sauaia,et al.  HMGB1 IS MARKEDLY ELEVATED WITHIN 6 HOURS OF MECHANICAL TRAUMA IN HUMANS , 2009, Shock.

[14]  T. Billiar,et al.  Mechanisms of Toll-Like Receptor 4 (TLR4)-Mediated Inflammation After Cold Ischemia/Reperfusion in the Heart , 2009, Transplantation.

[15]  A. Kudo,et al.  High mobility group box protein-1 in experimental autoimmune uveoretinitis. , 2009, Investigative ophthalmology & visual science.

[16]  Ye Wang,et al.  Potential role of macrophages in experimental keratomycosis. , 2009, Investigative ophthalmology & visual science.

[17]  S. Akira,et al.  ROLE OF TOLL-LIKE RECEPTORS 2 AND 4, AND THE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS IN HIGH-MOBILITY GROUP BOX 1-INDUCED INFLAMMATION IN VIVO , 2009, Shock.

[18]  H. Lee,et al.  Toll-like receptor 4 initiates an innate immune response to lipopolysaccharide in human conjunctival epithelial cells. , 2009, Experimental eye research.

[19]  Q. Gong,et al.  Protective Effect of Antagonist of High‐mobility Group Box 1 on Lipopolysaccharide‐Induced Acute Lung Injury in Mice , 2009, Scandinavian journal of immunology.

[20]  R. Medzhitov,et al.  Toll-like receptors and cancer , 2009, Nature Reviews Cancer.

[21]  M. Bianchi,et al.  Induction of inflammatory and immune responses by HMGB1–nucleosome complexes: implications for the pathogenesis of SLE , 2008, The Journal of experimental medicine.

[22]  N. Mukaida,et al.  Essential contribution of CCL3 to alkali-induced corneal neovascularization by regulating vascular endothelial growth factor production by macrophages , 2008, Molecular vision.

[23]  M. Capogrossi,et al.  High-mobility group box 1 protein in human and murine skin: involvement in wound healing. , 2008, The Journal of investigative dermatology.

[24]  M. Capogrossi,et al.  HMGB1-stimulated human primary cardiac fibroblasts exert a paracrine action on human and murine cardiac stem cells. , 2008, Journal of molecular and cellular cardiology.

[25]  R. J. Ross,et al.  Immunological protein expression profile in Ccl2/Cx3cr1 deficient mice with lesions similar to age-related macular degeneration. , 2008, Experimental eye research.

[26]  Arjan W. Griffioen,et al.  Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1) , 2008, Angiogenesis.

[27]  M. Rosengart,et al.  HMGB1 release induced by liver ischemia involves Toll-like receptor 4–dependent reactive oxygen species production and calcium-mediated signaling , 2007, The Journal of experimental medicine.

[28]  Laurence Zitvogel,et al.  Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy , 2007, Nature Medicine.

[29]  C. Baudouin,et al.  LPS-stimulated inflammation and apoptosis in corneal injury models. , 2007, Molecular vision.

[30]  B. Huang,et al.  Extracellular Hmgb1 Functions as an Innate Immune‐Mediator Implicated in Murine Cardiac Allograft Acute Rejection , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[31]  E. Chavakis,et al.  High-Mobility Group Box 1 Activates Integrin-Dependent Homing of Endothelial Progenitor Cells , 2007, Circulation research.

[32]  Hongli Li,et al.  Toll-like receptor 4 in atherosclerosis , 2007, Journal of cellular and molecular medicine.

[33]  D. Pisetsky,et al.  The Relationship between Apoptosis and High-Mobility Group Protein 1 Release from Murine Macrophages Stimulated with Lipopolysaccharide or Polyinosinic-Polycytidylic Acid , 2007 .

[34]  M. Cancino-Diaz,et al.  Lipopolysaccharide from Escherichia coli induces the expression of vascular endothelial growth factor via toll-like receptor 4 in human limbal fibroblasts. , 2006, Experimental eye research.

[35]  K. Tracey,et al.  HMGB1 SIGNALS THROUGH TOLL-LIKE RECEPTOR (TLR) 4 AND TLR2 , 2006, Shock.

[36]  Ashok Kumar,et al.  Toll-like receptors and corneal innate immunity. , 2006, Current molecular medicine.

[37]  H. S. Warren,et al.  Toll-like receptors. , 2005, Critical care medicine.

[38]  R. Darveau,et al.  MD-2 Mediates the Ability of Tetra-Acylated and Penta-Acylated Lipopolysaccharides to Antagonize Escherichia coli Lipopolysaccharide at the TLR4 Signaling Complex1 , 2005, The Journal of Immunology.

[39]  K. Tracey,et al.  The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion , 2005, The Journal of experimental medicine.

[40]  P. Rogalla,et al.  Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. , 2005, The American journal of pathology.

[41]  Kevin J. Tracey,et al.  High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal , 2005, Nature Reviews Immunology.

[42]  D. Golenbock,et al.  Activation of toll-like receptor (TLR)2, TLR4, and TLR9 in the mammalian cornea induces MyD88-dependent corneal inflammation. , 2005, Investigative ophthalmology & visual science.

[43]  O. Feron,et al.  Innate immunity and angiogenesis. , 2004, Circulation research.

[44]  Jingtai Cao,et al.  VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. , 2004, The Journal of clinical investigation.

[45]  E. Abraham,et al.  Involvement of Toll-like Receptors 2 and 4 in Cellular Activation by High Mobility Group Box 1 Protein* , 2004, Journal of Biological Chemistry.

[46]  M. Bianchi,et al.  Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation , 2004, The Journal of cell biology.

[47]  Joan W. Miller,et al.  VEGF164-mediated Inflammation Is Required for Pathological, but Not Physiological, Ischemia-induced Retinal Neovascularization , 2003, The Journal of experimental medicine.

[48]  K. Csaky,et al.  Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. , 2003, Investigative ophthalmology & visual science.

[49]  J. Ambati,et al.  Macrophage depletion inhibits experimental choroidal neovascularization. , 2003, Investigative ophthalmology & visual science.

[50]  Stefan Joos,et al.  HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[51]  T. Hisatomi,et al.  The critical role of ocular‐infiltrating macrophages in the development of choroidal neovascularization , 2003, Journal of leukocyte biology.

[52]  K. Tracey,et al.  HMGB1 as a DNA‐binding cytokine , 2002, Journal of leukocyte biology.

[53]  T. Misteli,et al.  Release of chromatin protein HMGB1 by necrotic cells triggers inflammation , 2002, Nature.

[54]  D. Golenbock,et al.  Cutting Edge: The Immunostimulatory Activity of the Lung Surfactant Protein-A Involves Toll-Like Receptor 41 , 2002, The Journal of Immunology.

[55]  B. Cronstein,et al.  Synergistic up-regulation of vascular endothelial growth factor expression in murine macrophages by adenosine A(2A) receptor agonists and endotoxin. , 2002, The American journal of pathology.

[56]  Carsten J. Kirschning,et al.  HSP70 as Endogenous Stimulus of the Toll/Interleukin-1 Receptor Signal Pathway* , 2002, The Journal of Biological Chemistry.

[57]  Noam Brown,et al.  Microenvironmental influence on macrophage regulation of angiogenesis in wounds and malignant tumors , 2001, Journal of leukocyte biology.

[58]  M. Goebeler,et al.  Chemokines in cutaneous wound healing , 2001, Journal of leukocyte biology.

[59]  T. Kislinger,et al.  Blockade of RAGE–amphoterin signalling suppresses tumour growth and metastases , 2000, Nature.

[60]  J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[61]  Cord Sunderkötter,et al.  Macrophages and angiogenesis , 1994, Journal of leukocyte biology.

[62]  K. Schulze-Osthoff,et al.  Macrophage-derived angiogenesis factors. , 1991, Pharmacology & therapeutics.